Congenital Adrenal Hyperplasia
Neurocrine Biosciences has completed a Phase I investigational new drug (IND)-opening study of NBI-74788 in healthy volunteers. The study was a randomized, open-label, two-period crossover study to evaluate the pharmacokinetics and safety of NBI-74788 in a total of 16 adults.
Neurocrine Biosciences is conducting a Phase II proof-of-concept study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of NBI-74788 in adult patients with classic congenital adrenal hyperplasia (CAH). The interim results from this ongoing open-label, multiple-dose, dose-escalation study were reported in March 2019. For more information on this Phase II study of NBI-74788 in CAH (CAHlibrate), please visit www.cahlibratestudy.com.